Crescent Biopharma, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $81.6M | $90.3M |
| FY2022 | — | $42.9M | $47.9M |
| FY2023 | — | $38.4M | $41.8M |
| FY2024 | — | $0 | $0 |
| FY2025 | — | $203.0M | $213.2M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $81.6M | $90.3M |
| FY2022 | — | $42.9M | $47.9M |
| FY2023 | — | $38.4M | $41.8M |
| FY2024 | — | $0 | $0 |
| FY2025 | — | $203.0M | $213.2M |